We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App





New Yeast-Based COVID-19 Diagnostic Test Could Detect SARS-CoV-2 in Saliva Faster Than RT-PCR

By HospiMedica International staff writers
Posted on 01 Feb 2021
A rapid COVID-19 diagnostic test based on a reaction between yeast and the novel coronavirus, will rapidly detect the presence of SARS-CoV-2 in saliva and will be available by mid-2021.

The yeast-based COVID-19 diagnostic test being developed by BIOinFOOD (São Paulo, Brazil) uses a biosensor consisting of a genetically modified brewer's yeast (Saccharomyces cerevisiae), which changes color if human ACE2 receptor expressed by the yeast's membrane binds to the spike glycoprotein present on the external surface of the virus.

The innovation involved in the COVID-19 diagnostic test came out of a technology mastered previously by BIOinFOOD. More...
The firm offers a biotech platform based on S. cerevisiae, a versatile microorganism widely used in industry as a biofactory. Organic acids, amino acids, enzymes, and therapeutic proteins are some of the outputs of the platform. The firm also develops custom yeasts for use by bakeries and breweries to suit consumer tastes.

According to the researchers' expectations, the new test will be both fast and cheaper than RT-PCR because of the low cost of yeast, the main input. Another important difference is that it will probably use saliva. Being non-invasive is an advantage for diagnostic tests. Many people experience intense discomfort when undergoing collection of their material by nasal swab. Additionally, the sensitivity of the test is expected to be high, meaning it will be able to detect the virus only a few days after infection. Once the working hypothesis has been fully validated, the scientists expect the test to be brought to market and freely available for purchase during first-half 2021. The raw materials for the product are simple and distribution of the diagnostic test should be logistically straightforward.

"The yeast is normally beige. When this interaction takes place, the presence of the virus is signaled by a fluorescent green that can easily be detected by the equipment typically found in clinical analysis labs," said Gleidson Silva Teixeira, one of BIOinFOOD's partners. "We plan eventually to have the yeast emit red light, which will be easier to identify. In this case, anyone will be perfectly capable of using the test, even at home."

Related Links:
BIOinFOOD


Gold Member
12-Channel ECG
CM1200B
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Radiation Safety Barrier
RayShield Intensi-Barrier
VTE Prevention System
Flowtron ACS900
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.